Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine

Eli Lilly announced positive Phase 3 results for its oral GLP-1 receptor agonist, orforglipron, published in The New England Journal of Medicine, demonstrating an average A1C reduction of 1.3% to 1.6% and an average weight loss of 7.9% (16.0 lbs) at the highest dose after 40 weeks in adults with type 2 diabetes. The safety profile was consistent with injectable GLP-1s, with the most common adverse events being mild-to-moderate gastrointestinal issues, and Lilly plans to submit orforglipron for regulatory approval for weight management by the end of this year and for type 2 diabetes in 2026, potentially offering a convenient oral alternative to injectables.

Analysis

Eli Lilly's oral GLP-1 asset, orforglipron, has demonstrated compelling efficacy in its Phase 3 ACHIEVE-1 trial, with results published in the New England Journal of Medicine, lending significant credibility to the data. The drug met its primary endpoint with a superior A1C reduction of 1.3% to 1.6% versus placebo, alongside a meaningful secondary endpoint of up to 7.9% average weight loss at the highest dose over 40 weeks. This positions orforglipron as a potent oral treatment option. The safety profile, characterized by mild-to-moderate gastrointestinal events consistent with the GLP-1 class and manageable discontinuation rates (4-8%), appears favorable. The key strategic advantage is its formulation as a once-daily pill without food or water intake restrictions, presenting a significant convenience benefit over injectable therapies and potentially other oral competitors. Upcoming catalysts are critical, particularly head-to-head trial results against dapagliflozin and oral semaglutide later this year, which will define its competitive standing. The company's timeline, with a weight management submission planned for late 2024 and a diabetes submission in 2026, signals a clear strategy to compete aggressively in both high-growth markets.

Key Decisions for Investors

• The robust Phase 3 data for orforglipron significantly de-risks a key pipeline asset, reinforcing Eli Lilly's dominant position and long-term growth outlook in the metabolic disease market.
• Investors should closely monitor the upcoming results from the ACHIEVE-2 and ACHIEVE-3 trials later this year, as performance against competitors like oral semaglutide will be a crucial determinant of market share and commercial potential.
• The convenience of a once-daily oral pill without food restrictions represents a substantial commercial opportunity to capture patients averse to injectables, potentially expanding the GLP-1 market and providing a distinct growth driver for the company.